Cantor Starts Innoviva at Overweight, Cites Diversified Business Model
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA), citing the company's unique business model centered around royalties and healthcare assets.The company receives royalties from
Innoviva Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 — Cantor Fitzgerald Initiates Coverage On → Overweight 05/10/2023 39.23% EF Hutton → $22.5 Rei
Cantor Fitzgerald Initiates Innoviva(INVA.US) With Buy Rating
Cantor Fitzgerald analyst Louise Chen initiates coverage on $Innoviva(INVA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 39.7% and a total average return of -9.0
Express News | Innoviva Inc : Cantor Fitzgerald Initiates Coverage With Overweight Rating
21% Of This Innoviva Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Innoviva, Inc.'s (NASDAQ:INVA ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it. While insid
Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as New Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced the appoint
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PDF Version BURLINGAME, Calif.--(BUSINESS WIRE)--Jun. 3, 2024-- Innoviva, Inc. (Nasdaq: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leadi
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter B
Innoviva Updates Investor Presentation on Website
Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
Innoviva Q1 EPS $0.46 Beats $0.17 Estimate, Sales $77.50M Beat $68.00M Estimate
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.17 by 170.59 percent. This is a 9.52 percent increase over earnings of $0.42 per s
Innoviva | 10-Q: Quarterly report
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M
04:44 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M
Express News | Innoviva Inc: Cash and Cash Equivalents Totaled $178.4 Mln as of March 31, 2024.
Express News | Innoviva Inc: Qtrly Shr - Basic $0.58
Press Release: Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $1
No Data